BMS 299897 is primarily researched for its potential in treating Alzheimer's disease. It functions as a gamma-secretase inhibitor, targeting the enzyme involved in the production of amyloid-beta peptides. These peptides are known to accumulate in the brains of Alzheimer's patients, forming plaques that disrupt neural function. By inhibiting gamma-secretase, BMS 299897 aims to reduce amyloid-beta production, potentially slowing disease progression. Its application is focused on preclinical and clinical studies to evaluate its efficacy and safety as a therapeutic agent for neurodegenerative conditions.